ClinicalTrials.gov
public full text
Public Domain
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for Acute Heart Failure (AHF).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure#994887
- The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure#846269
- Training Intervention in Heart Failure and Frail Elderly Population#980610
- Effects of sacubitril-valsartan on aging-related cardiac dysfunction#330433
- Development and validation of a machine learning-based clinical decision support tool for stratifying intravenous medication risk in hospitalized patients with heart failure#368924
Record · ID 897299
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive